Australia GDP Beats Forecast, Boosting RBA Rate Hike Bets 
CIA-Linked Investor Helped Quantum Systems Expand in US 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
RBNZ Raises Interest Rate to 2.75%, Kiwi Dollar Slides 
Canada Backs €100 Billion Global Defence Bank 
Amazon Shares Fall as FTC Plans Ad Pricing Lawsuit 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
Asian Currencies Weaken as Dollar Rises, Kiwi Slides After RBNZ Hike 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Gold Prices Steady as U.S.-Iran Tensions Lift Inflation Risks 
Asian Tech Stocks Slide as Fed Rate Hike Bets Rise 
Shein Shares Drop 5% After Weak Hong Kong IPO Debut 
US Strikes Iran IRGC Targets as Conflict Escalates 
South Korea Inflation Rises to 3.1% in August 
Apple’s Phil Schiller Steps Back as Leadership Shake-Up Accelerates 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Add as a preferred source on Google
Samsung Biologics contradicted reports that it will be producing Pfizer’s coronavirus vaccine. There were news going around saying the South Korean biotechnology company headquartered in Incheon is set to start the production of the said American pharmaceutical corp’s COVID-19 vaccine soon.
False manufacturing deal report?
As per The Korea Herald, Samsung Biologics said that the report that was published by the Korea Economic Daily was “not factual.” In the report, it was claimed that the Korean firm is in talks with Pfizer for a manufacturing deal.
An unnamed source from the government allegedly said, “If all goes well, the company will be able to begin mass production of the vaccine in August at the earliest.”
However, Samsung Biologics is saying there is no such deal and not even a discussion about any contract to produce the vaccines for Pfizer. Besides, the American pharma company does not appear to have a problem in producing huge amounts of vaccine doses by itself.
In fact, Bloomberg reported just last week that Pfizer and BioNTech can produce as many as 3 billion doses of their coronavirus vaccine in this year alone. This is said to be more than double the number that the company’s partners had predicted six months ago.
What’s more, Pfizer and BioNTech are reportedly further increasing their production capacity for next year. They are aiming to manufacture more than 3 billion vials of the vaccine. The boost in production comes as the demand has also surged around the world.
Pfizer also deny production outside of its manufacturing lines
It was reported that Pfizer is exclusively manufacturing its own vaccine in its two dedicated supply lines located in Europe and the U.S. The doses made here are for global distribution.
“At this time, we are not in discussions for any additional manufacturing outside these established supply lines for this vaccine,” Pfizer said. “Once the pandemic supply phase is over and we enter a phase of regular supplies, Pfizer will certainly evaluate all additional opportunities available.”
Meanwhile, South Korea is one of the countries that are waiting for deliveries of Pfizer vaccines. It was said that the Korean government has a contract with the vaccine maker for the supply of 66 million doses of its COVID-19 vaccine.
